Rani Therapeutics

Happy 4th of July! Today and every day we have immense gratitude and celebrate our great America – the land of independence, opportunity, and innovation!  ❤️ 🗽 🎆 💙

Today we announced a definitive agreement with ProGen for the co-development and commercialization of RT-114, an oral RaniPill® capsule containing ProGen’s GLP-1/GLP-2 dual agonist, for the treatment of obesity. RT-114 is designed to provide a differentiated oral delivery mechanism with the potential to offer advantages over other weight management candidates in development.  https://lnkd.in/gTM5sxKN #OralDelivery #OralBiologics #RaniPill #RaniTherapeutics #obesity #GLP

We are excited to announce that Rani Therapeutics will be presenting at the Next Gen Peptide Formulation & Delivery Summit which will be held in Boston from June 18-20. Our VP, Medical Affairs, Dr. Jacques Van Dam, will be presenting the clinically relevant bioavailability the RaniPill has demonstrated when delivering peptides across numerous therapeutic areas. To learn more about this conference go to: https://bit.ly/3yXWh09 #RaniTherapeutics #RaniPill #NextGenPeptideSummit #PeptideDeliveryInnovation

Our Business Development team is heading to San Diego for the Biotechnology Innovation Organization International Convention! Looking forward to discussing partnership opportunities for our RaniPill drug-agnostic oral delivery technology and networking with fellow industry professionals throughout the week. #BIO2024 #RaniPill #RaniTherapeutics

This Memorial Day weekend, we remember those who gave the ultimate sacrifice while serving the United States of America. At Rani Therapeutics, we are grateful, and we honor you. #memorialday2024 #RaniTherapeutics

It was a great week at #DDW2024! We enjoyed visiting with colleagues and industry partners as well as presenting our preclinical and Phase 1 clinical data from RT-111, a RaniPill® capsule containing an ustekinumab #biosimilar, CT-P43. RT-111 was well-tolerated and delivered ustekinumab with high bioavailability. RT-111 has the potential to offer a highly differentiated dosing regimen in psoriasis compared to injectable biologics, oral small molecules, and peptides. These data mark another significant milestone in our progress towards making oral biologics a reality for the millions of patients living with autoimmune conditions. #OralDelivery #OralBiologics #RaniPill #RaniTherapeutics

Join me at the world’s largest and most comprehensive gathering of digestive disease clinicians, researchers and industry as we share the latest updates on oral biologics with the RaniPill. "Orally-Administered Ustekinumab Biosimilar RT-111 Delivered Via a Robotic Pill Yields Bioavailability Comparable to Subcutaneous Injection in Canines" Tuesday May 21st 12:30PM EDT See you there! #RaniPill #OralBiologics #gastroenterology #hepatology #digestivediseases #DDW2024

Don't miss our presentations at Digestive Disease Week® 2024! 🌟 Rani Therapeutics is set to redefine biologic drug delivery with our groundbreaking RaniPill® capsule. Join us at DDW 2024, both virtually and in-person from May 18-21, 2024, in Washington, DC to see Rani’s RT-111 preclinical and clinical data. For more details and access to the presentations, visit https://bit.ly/2vA5jfO. #RaniTherapeutics #DDW2024 #BiologicDrugDelivery #InnovationInProgress 🚀🔬

Honored to announce that our CFO, Svai Sanford has been recognized as one of the Top 25 CFOs of San Francisco for 2024 by TOP CFOs! 🏆 🌟 This recognition is a testament to Svai’s leadership and financial acumen, which has greatly impacted our growth over his 7 years as Rani's CFO. Join us in celebrating this achievement! Read more: https://bit.ly/3U7CylH #BayArea #SF #TopCFOs

Celebrating International Women's Day with our incredible team! Today, we asked our female colleagues to share quotes from women that inspire them in work and life. Here are some moments captured. Let's continue to uplift, inspire, and empower each other every day. #InternationalWomensDay #WomenEmpowerment